Background & Aim: Point-of-care (POC) manufacturing of CAR-T cells using the Miltenyi Biotec CliniMACS Prodigy® has the potential to expand the availability of CAR-T cell treatment. Methods, Results & Conclusion: We initiated a phase I clinical trial in adults with relapsed and / or refractory CD19- positive haematological malignancy who are ineligible for CAR-T cells that are clinically approved and funded by the government (Trial ID: ACTRN12621000762853). Mononuclear cells (MNC(A)) collected by apheresis (maximum of 3x109 CD3+ T cells) were loaded without prior cryopreservation onto the Prodigy® for selection of CD4+ and CD8+ T cells. A total of 1 x108 T cells were activated with Transact® and transduced with the CD19 4-1BB-based CAR lentiviral vector, LTG1563 (Lentigen) 24h later. Cells were expanded for a further 11 days in TexMACS GMP medium supplemented with IL-7 and IL-15. Quality assurance testing was performed on the MNC(A), CD4+/CD8+ selected MNC(A), in-process samples on days 5, 9 and 12, and on the formulated CAR-T cells. CAR-T cells were released and infused without cryopreservation on day 12 of manufacture. Patients were lymphodepleted with fludarabine and cyclophosphamide. The target cell doses were 0.5 x106 viable CD3+CAR+ cells/kg for patients at high risk for cytokine release syndrome and 2.0 x106 viable CD3+CAR+ cells/kg for those at standard risk. A total of four patients have been enrolled to date. CAR-T cell manufacture met specification for viability, transduction efficiency, microbial contamination, mycoplasma, endotoxin, and qPCR for replication competent lentivirus (RCL) and lentiviral copy number. One patient with target cell dose of 37.5 x10^6 cells received only 6.7 x106 CAR T cells. This patient with mantle cell lymphoma died from progressive disease at day +23 post-infusion. The remaining three patients received target cell doses of 220.0, 184.0, and 61.5 x106 CAR-T cells, with actual available CAR T cell doses being 1.15, 1.15 and 1.22 x109 CAR-T cells. CAR-T cells were readily detectable by flow cytometry from day 7 post-infusion in these 3 patients, who remain alive at 1 to 6 months: 2 in complete remission (1 follicular lymphoma, 1 B-ALL), 1 with stable disease (B-ALL). None of the patients developed grade > 2 CRS or ICANS. POC manufacture is feasible and enables the infusion of a CAR-T product with a short needle-to-needle time of 12 days. The development of POC manufacture provides a platform for future clinical translation of novel CAR-T cells.